|
Case registration
|
New case
|
77 (8.3)
|
|
Relapse
|
124 (13.3)
|
|
After failure of first treatment
|
213 (22.9)
|
|
After failure of re-treatment
|
442 (47.5)
|
|
Treatment after being lost to follow- up
|
4 (0.4)
|
|
Transfer -in
|
2 (0.2)
|
|
Other
|
11 (1.2)
|
|
TB treatment in the past
|
Yes
|
788 (84.6)
|
|
No
|
63 (6.8)
|
|
Unknown
|
27 (2.9)
|
|
Treatment taken for past TB
|
First-line drugs
|
792 (85.1)
|
|
Second- line drugs
|
25 (2.7)
|
|
Both first and second line drugs
|
4 (0.4)
|
|
Second- line past injectable treatment
|
Kanamycin
|
1 (0.1)
|
|
Amikacin
|
6 (0.6)
|
|
Capreomycin
|
17 (1.8)
|
|
Streptomycin
|
33 (3.5)
|
|
Anatomical site TB
|
Pulmonary
|
817 (87.8)
|
|
Extrapulmonary
|
59 (6.3)
|
|
MTB detection
|
Bacteriologically confirmed MDR-TB
|
850 (91.3)
|
|
Clinically diagnosed MDR-TB
|
27 (2.9)
|
|
NA
|
2 (0.2)
|
|
MTB confirmation
|
GeneXpert MTB/RIF positive
|
347 (37.5)
|
|
Culture
|
234 (25.1)
|
|
Line probe assay
|
214 (23.0)
|
|
Sputum smear positive
|
29 (3.1)
|
|
Resistance /Sensitivity testing
|
GeneXpert MTB/RIF
|
356 (38.2)
|
|
Line probe assay
|
232 (24.9)
|
|
Phenotypic drug susceptibility testing
|
242 (26.0)
|
|
NA + other
|
42 (4.7)
|
|
HIV status
|
HIV positive MDR-TB patients
|
171 (18.4)
|
|
HIV negative MDR-TB patients
|
685 (73.6)
|
|
HIV status unknown MDR-TB patients
|
23 (2.4)
|
|
Pattern of resistance
|
Isoniazid and rifampicin resistance
|
341 (40.1)
|
|
GeneXpertMTB/RIF rifampicin only resistance
|
260 (30.6)
|
|
Rifampicin resistance with isoniazid susceptibility
|
38 (4.5)
|
|
Isoniazid, rifampicin, ethambutol, streptomycin, resistance
|
132 (15.5)
|
|
Isoniazid, rifampicin and streptomycin resistance
|
1 (0.1)
|
|
Others
|
94 (10.1)
|
